Inclusion Criteria:~1. Able to comprehend and willing to sign an informed consent form (ICF) and their ability
to consent was estimated by an independent Neurologist or Geriatrist.~2. Males or females between the ages of
55 and 85 years of age, inclusive~3. Diagnosis of probable AD with evidence of the AD pathophysiological
process according to the diagnostic criteria of the National Institute on Aging and Alzheimer's Association~4.
AD patients with a score of 18 to 24 on MMSE at screening.~5. Subjects may be treated in parallel with
rivastigmine, donepezil, galantamine, memantine, donezepil, aducanumab, and lecanemab or their combination. For
rivastigmine, donepezil, galantamine, memantine, donezepil - 30 days of stable use prior to enrollment is
required. For aducanumab and lecanemab - 3 months of stable use prior to enrollment is required.~6. 18 < BMI <
30~7. Patients who have a caregiver - the caregiver shall be in contact with the patient at least 10 hours per
week, and can attend all visits with the patient, report on the subject's status and verify compliance with all
study requirements.~8. CT or MRI available within 12 months before the enrolment to the study devoid of any
structural finding which could explain the cognitive impairment, except for brain atrophy or white matter
hyperintensities which can be observed in AD patients.~9. CT or MRI available within 3 months before the lumbar
puncture.~10. Presence of pTau 181 in CSF at screening~11. Female with no childbearing potential (at least 1
year postmenopausal or surgical contraception)~
